[{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Caspofungin","moa":"1,3-beta-glucan synthase","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Caspofungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Bristol Myers Squibb | Onyx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ Bristol Myers Squibb | Onyx Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Bristol Myers Squibb | Onyx Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Carvedilol","moa":"Adrenergic receptor beta | Adrenergic receptor alpha-1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Children's Oncology Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mercaptopurine","moa":"Amidophosphoribosyltransferase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Alessa Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bicalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Alessa Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"VT-464","moa":"Androgen Receptor | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Trebananib","moa":"Angiopoietin-1 | Angiopoietin-2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Asparaginase","moa":"Asparagine","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Cartesian Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Descartes-11","moa":"BCMA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Plus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"QSAM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Canadian Cancer Trials Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GI-6207","moa":"Carcinoembryonic antigen CEA (CD66e)","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Acetyl-L-Carnitine HCl","moa":"Carnitine acetyl","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Vergent Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VGT-309","moa":"Cathepsin","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ichnos Glenmark Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"GRC 65327","moa":"Cbl-b","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"Inotuzumab ozogamicin","moa":"CD22","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Senti Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Funding","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"ALT-801","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Celgene Corporation"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GigaGen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Anastrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"OncoC4","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Onc-392","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"hu14.18-IL2","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Privo Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Privo Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"4-demethyl-4-cholesteryloxycarbonylpenclomedine","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bleomycin Sulphate","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Busulfan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Canadian Cancer Trials Group | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Canadian Cancer Trials Group | NRG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Canadian Cancer Trials Group | NRG Oncology"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Abbott Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Abbott Laboratories"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Immatics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Prescient Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"DM-CHOC-PEN","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DM-CHOC-PEN","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Children's Oncology Group","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Children's Oncology Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methoxyamine","moa":"||DNA base excision repair pathway","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Children's Oncology Group | LLS PedAL","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Children's Oncology Group | LLS PedAL","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Children's Oncology Group | LLS PedAL"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ProLynx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ United Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Shasqi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Children's Oncology Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"VK-2019","moa":"EBNA-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Plus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"Rhenium","moa":"Emitter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Crizotinib","moa":"EML4-ALK | Hepatocyte growth factor receptor | ALK tyrosine kinase receptor | NPM\/ALK (Nucleophosmin\/ALK tyrosine kinase receptor)","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Crizotinib","moa":"EML4-ALK | Hepatocyte growth factor receptor | ALK tyrosine kinase receptor | NPM\/ALK (Nucleophosmin\/ALK tyrosine kinase receptor)","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crizotinib","moa":"EML4-ALK | Hepatocyte growth factor receptor | ALK tyrosine kinase receptor | NPM\/ALK (Nucleophosmin\/ALK tyrosine kinase receptor)","graph1":"Oncology","graph2":"Approved FDF","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"Extracellular calcium-sensing receptor; Calreticulin; Calcium and integrin-binding protein 1; Programmed cell death protein 6; Sorcin; Calcineurin B homologous protein 1; SPARC; Calnexin; Fibrillin-2; Protein S100-B; Calsequestrin-2; Regucalcin; Peflin; Protein S100-A6; Translationally-controlled tumor protein; Calcium and integrin-binding family member 2; Protein S100-A13; Calsequestrin-1; Nucleobindin-1; Nucleobindin-2; Fibrillin-3; Grancalcin; Calcium-dependent secretion activator 1; Calmodulin-2; Calmodulin-3; Protein S100-A16; Calretinin; Calcyphosin; Calcium-dependent secretion activator 2; Calreticulin-3; Neurexin-1; Neuronal calcium sensor 1; Calmodulin","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Soligenix","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"11","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Dalantercept","moa":"Growth\/differentiation factor 2 | Bone morphogenetic protein 10","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Dalantercept","moa":"Growth\/differentiation factor 2 | Bone morphogenetic protein 10","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Celgene Corporation"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Children's Oncology Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PRGN-2012","moa":"HPV6\/HPV11","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"18-F Fluoromisonidazole","moa":"Hypoxia","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Neumedicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"NM-IL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sinecatechins","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Proagio","moa":"Integrin-alpha-5\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Syntrix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SX-682","moa":"Interleukin-8 receptors, CXCR1\/CXCR2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ALT-803","moa":"interleukins","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"NT-I7","moa":"interleukins: interleukin-7 analogues and derivatives; Fc fusion protein","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ NeoImmuneTech","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ NeoImmuneTech"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Children's Oncology Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Elicio Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NextCure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NC525","moa":"||LAIR-1","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase receptor RET | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Canadian Cancer Trials Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Enzomenib","moa":"MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"MSLN","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"eRapa","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"PDS0103","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ PDS Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ PDS Biotechnology"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Lorvotuzumab Mertansine","moa":"Neural cell adhesion molecule 1 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Undisclosed","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Larotrectinib","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Myosin Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"MT-125","moa":"Non-Muscle Myosin II","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"AstraZeneca | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ AstraZeneca | NRG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ AstraZeneca | NRG Oncology"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Canadian Cancer Trials Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Lumicell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LUM015","moa":"PEGylated compounds","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Lumicell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LUM015","moa":"PEGylated compounds","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Institutes of Health Clinical Center | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluciclatide","moa":"peptides","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Institutes of Health Clinical Center | GE Healthcare","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Institutes of Health Clinical Center | GE Healthcare"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Blaze Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Tozuleristide","moa":"peptides","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Canadian Cancer Trials Group | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Canadian Cancer Trials Group | NRG Oncology","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ Canadian Cancer Trials Group | NRG Oncology"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Canadian Cancer Trials Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enzastaurin","moa":"Protein kinase C beta","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"N-803","moa":"receptor molecules","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Clofarabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Uprosertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ GSK"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alisertib","moa":"Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ GSK"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GSK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ GSK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ GSK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Prexasertib","moa":"Serine\/threonine-protein kinase Chk2 | Serine\/threonine-protein kinase Chk1","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Aadi Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ABI-009","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Tvardi Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Canadian Cancer Trials Group | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cediranib","moa":"Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Canadian Cancer Trials Group | NRG Oncology","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ Canadian Cancer Trials Group | NRG Oncology"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"GI-6301","moa":"T-box transcription factor T (TBXT)","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2013","type":"Inapplicable","leadProduct":"Imetelstat Sodium","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"Imetelstat Sodium","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2010","type":"Inapplicable","leadProduct":"Seneca Valley Virus-001","moa":"TEM8","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"VTX-2337","moa":"Toll-like receptor 8","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ Sapience Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Sapience Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Funding","leadProduct":"ST101","moa":"T-type calcium channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Mercator MedSystems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Cellectar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CLR131","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Celgene Corporation"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"XEME Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Oncoquest-CLL Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Bone Marrow Aspiration","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bone Marrow Aspiration","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Bone Marrow Aspiration","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Bone Marrow Aspiration","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bone Marrow Aspiration","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"Bria-PROS-Plus","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NRG Oncology | Radiation Therapy Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cediranib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ NRG Oncology | Radiation Therapy Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ NRG Oncology | Radiation Therapy Oncology Group"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"UNII-38R1Q0L1ZE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum Strain 299","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lumbar Puncture","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Peg-Pei-Cholesterol Lipopolymer","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Peg-Pei-Cholesterol Lipopolymer","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Plasmid DNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Inovio Pharmaceuticals"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Radiation","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Hackensack Meridian Health | Georgetown University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Rapamycin-resistant, Th1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Hackensack Meridian Health | Georgetown University","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Hackensack Meridian Health | Georgetown University"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RVP-001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"TF2","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Versamune-TARP","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"MD Anderson Cancer Center | Genentech | Merck & Co | Brain Tumor Trials Collaborative | Ohio State University | Northwestern University Feinberg School of Medicine | UF Health Cancer Center at Orlando Health | Baylor Health Care System | MUSC Hollings Can","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ MD Anderson Cancer Center | Genentech | Merck & Co | Brain Tumor Trials Collaborative | Ohio State University | Northwestern University Feinberg School of Medicine | UF Health Cancer Center at Orlando Health | Baylor Health Care System | MUSC Hollings Can","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ MD Anderson Cancer Center | Genentech | Merck & Co | Brain Tumor Trials Collaborative | Ohio State University | Northwestern University Feinberg School of Medicine | UF Health Cancer Center at Orlando Health | Baylor Health Care System | MUSC Hollings Can"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Brivanib Alaninate","moa":"Vascular endothelial growth factor receptor | Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Exelixis"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tegavivint","moa":"vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Eureka Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Eureka Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Endure Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Biosplice","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"}]

Find Clinical Drug Pipeline Developments & Deals by National Cancer Institute

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Belzutifan is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 18, 2025

                          Lead Product(s) : Belzutifan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : NYU Langone Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways, being investigated for AML.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 09, 2025

                          Lead Product(s) : Cirtuvivint

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Biosplice

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : The funding will support Phase I dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with glioblastoma.

                          Product Name : MT-125

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          August 19, 2025

                          Lead Product(s) : MT-125

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Myosin Therapeutics

                          Deal Size : $4.5 million

                          Deal Type : Funding

                          blank

                          04

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : The funding will support the development of a novel Engineered Native Bacteria (ENB) candidate for the treatment of Familial Adenomatous Polyposis (FAP).

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          August 12, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : Endure Bio

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          05

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Bortezomib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Multiple Myeloma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 25, 2025

                          Lead Product(s) : Bortezomib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Eastern Cooperative Oncology Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Glioblastoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 22, 2025

                          Lead Product(s) : Aminolevulinic Acid HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Mayo Clinic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Leucovorin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Stomach Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 03, 2025

                          Lead Product(s) : Calcium Folinate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : ECOG-ACRIN Cancer Research Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : The collaboration aims to evaluate DSP-5336 (enzomenib), an oral, small molecule designed to inhibit the menin and KMT2A protein interaction present in certain difficult to treat cancers.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          April 14, 2025

                          Lead Product(s) : Enzomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Sumitomo Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : The trial will evaluate the triplet combination comprised of Actimab-A, Venetoclax, an oral Bcl-2 inhibitor and ASTX-727, a novel oral hypomethylating agent in frontline AML patients.

                          Product Name : Actimab-A

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 11, 2025

                          Lead Product(s) : Ac-225 Lintuzumab,Cedazuridine,Decitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Actinium pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor and cedazuridine, a cytidine deaminase inhibitor. It is being evaluated for IDH2-Mutated Myelodysplastic Syndrome.

                          Product Name : Inqovi

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 14, 2025

                          Lead Product(s) : Cedazuridine,Decitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Taiho Oncology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank